Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niklas Mattsson

Showing results (101-110 of 395) with videos related to

Pageof 40
Sort By:
Neurology|January 11, 2019
Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer diseaseRik Ossenkoppele, Ruben Smith, Tomas Ohlsson, et al.
Brain Communications|March 17, 2023
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's diseaseNicholas C Cullen, Shorena Janelidze, Erik Stomrud, et al.
Brain Communications|April 24, 2023
Polygenic risk of type 2 diabetes is associated with incident vascular dementia: a prospective cohort studyElin Dybjer, Atul Kumar, Katarina Nägga, et al.
Neurobiology of Aging|November 19, 2019
Apathy and anxiety are early markers of Alzheimer's diseaseMaurits Johansson, Erik Stomrud, Olof Lindberg, et al.
Brain Communications|June 15, 2022
Astrocytic function is associated with both amyloid-β and tau pathology in non-demented <i>APOE ϵ4</i> carriersNicola Spotorno, Chloé Najac, Erik Stomrud, et al.
Journal of Alzheimer'S Disease : JAD|April 6, 2012
Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairmentNiklas Mattsson, Erik Portelius, Sindre Rolstad, et al.
Biomarkers in Medicine|August 25, 2012
Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkersNiklas Mattsson, Ulf Andreasson, Maria C Carrillo, et al.
Frontiers in Neuroscience|June 2, 2017
Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's DiseasePhilip S Insel, Rik Ossenkoppele, Devon Gessert, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 11, 2016
Assessing risk for preclinical β-amyloid pathology with <i>APOE</i>, cognitive, and demographic informationPhilip S Insel, Sebastian Palmqvist, R Scott Mackin, et al.
Alzheimer'S Research & Therapy|August 9, 2018
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort studyNiklas Mattsson, Rik Ossenkoppele, Ruben Smith, et al.
Pageof 40

Showing results (101-110 of 395) with videos related to

Sort By:
Pageof 40
Neurology|January 11, 2019
Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer diseaseRik Ossenkoppele, Ruben Smith, Tomas Ohlsson, et al.
Brain Communications|March 17, 2023
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's diseaseNicholas C Cullen, Shorena Janelidze, Erik Stomrud, et al.
Brain Communications|April 24, 2023
Polygenic risk of type 2 diabetes is associated with incident vascular dementia: a prospective cohort studyElin Dybjer, Atul Kumar, Katarina Nägga, et al.
Neurobiology of Aging|November 19, 2019
Apathy and anxiety are early markers of Alzheimer's diseaseMaurits Johansson, Erik Stomrud, Olof Lindberg, et al.
Brain Communications|June 15, 2022
Astrocytic function is associated with both amyloid-β and tau pathology in non-demented <i>APOE ϵ4</i> carriersNicola Spotorno, Chloé Najac, Erik Stomrud, et al.
Journal of Alzheimer'S Disease : JAD|April 6, 2012
Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairmentNiklas Mattsson, Erik Portelius, Sindre Rolstad, et al.
Biomarkers in Medicine|August 25, 2012
Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkersNiklas Mattsson, Ulf Andreasson, Maria C Carrillo, et al.
Frontiers in Neuroscience|June 2, 2017
Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's DiseasePhilip S Insel, Rik Ossenkoppele, Devon Gessert, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 11, 2016
Assessing risk for preclinical β-amyloid pathology with <i>APOE</i>, cognitive, and demographic informationPhilip S Insel, Sebastian Palmqvist, R Scott Mackin, et al.
Alzheimer'S Research & Therapy|August 9, 2018
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort studyNiklas Mattsson, Rik Ossenkoppele, Ruben Smith, et al.
Pageof 40